Vimarsana
Biggest News Aggregation in the World

Page 10 - Nasdaq Coll News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Nasdaq Coll. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Nasdaq Coll Today - Breaking & Trending Today

Emerald Mutual Fund Advisers Trust Has $15.91 Million Stock Holdings in Collegium Pharmaceutical, Inc. (NASDAQ:COLL) - Vimarsana News

Emerald Mutual Fund Advisers Trust Has $15.91 Million Stock Holdings in Collegium Pharmaceutical, Inc. (NASDAQ:COLL)

Emerald Mutual Fund Advisers Trust cut its stake in Collegium Pharmaceutical, Inc. (NASDAQ:COLL – Get Rating) by 1.4% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 685,893 shares of the specialty pharmaceutical company’s stock after selling 9,500 shares during the period. […]

Collegium Pharmaceutical, Inc. (NASDAQ:COLL) Shares Sold by MetLife Investment Management LLC - Vimarsana News

Collegium Pharmaceutical, Inc. (NASDAQ:COLL) Shares Sold by MetLife Investment Management LLC

MetLife Investment Management LLC cut its stake in Collegium Pharmaceutical, Inc. (NASDAQ:COLL – Get Rating) by 13.2% during the 4th quarter, according to its most recent Form 13F filing with the SEC. The fund owned 17,661 shares of the specialty pharmaceutical company’s stock after selling 2,676 shares during the period. MetLife Investment Management LLC owned […]

Source: wkrb13.com
Collegium Pharmaceutical, Inc. (NASDAQ:COLL) Receives Average Recommendation of "Buy" from Analysts - Vimarsana News

Collegium Pharmaceutical, Inc. (NASDAQ:COLL) Receives Average Recommendation of "Buy" from Analysts

Collegium Pharmaceutical, Inc. (NASDAQ:COLL – Get Rating) has been given a consensus rating of “Buy” by the seven analysts that are currently covering the firm, Marketbeat.com reports. One investment analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and four have given a buy recommendation to the company. The […]

Analysts Anticipate Collegium Pharmaceutical, Inc. (NASDAQ:COLL) to Post $1.42 Earnings Per Share - Vimarsana News

Analysts Anticipate Collegium Pharmaceutical, Inc. (NASDAQ:COLL) to Post $1.42 Earnings Per Share

Wall Street brokerages expect Collegium Pharmaceutical, Inc. (NASDAQ:COLL – Get Rating) to report earnings per share (EPS) of $1.42 for the current quarter, according to Zacks. Five analysts have made estimates for Collegium Pharmaceutical’s earnings, with estimates ranging from $1.25 to $1.75. Collegium Pharmaceutical reported earnings of $0.27 per share during the same quarter last […]

Collegium Pharmaceutical, Inc. (NASDAQ:COLL) Given Average Recommendation of "Buy" by Brokerages - Vimarsana News

Collegium Pharmaceutical, Inc. (NASDAQ:COLL) Given Average Recommendation of "Buy" by Brokerages

Collegium Pharmaceutical, Inc. (NASDAQ:COLL – Get Rating) has been assigned a consensus rating of “Buy” from the seven brokerages that are presently covering the company, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and four have assigned a buy rating to the […]